<code id='4EAB290D67'></code><style id='4EAB290D67'></style>
    • <acronym id='4EAB290D67'></acronym>
      <center id='4EAB290D67'><center id='4EAB290D67'><tfoot id='4EAB290D67'></tfoot></center><abbr id='4EAB290D67'><dir id='4EAB290D67'><tfoot id='4EAB290D67'></tfoot><noframes id='4EAB290D67'>

    • <optgroup id='4EAB290D67'><strike id='4EAB290D67'><sup id='4EAB290D67'></sup></strike><code id='4EAB290D67'></code></optgroup>
        1. <b id='4EAB290D67'><label id='4EAB290D67'><select id='4EAB290D67'><dt id='4EAB290D67'><span id='4EAB290D67'></span></dt></select></label></b><u id='4EAB290D67'></u>
          <i id='4EAB290D67'><strike id='4EAB290D67'><tt id='4EAB290D67'><pre id='4EAB290D67'></pre></tt></strike></i>

          leisure time

          leisure time

          author:focus    Page View:382
          Matts Take Column Illustration
          Molly Ferguson for STAT

          American medicine is a tragic paradox. An example: Cancer patients are likely dying as a result of drug shortages that occurred partly because generic chemotherapies have been allowed to become too cheap. At the same time, other patients are suffering, and perhaps dying, because the financial burden brought on by the expensive medicines they need is too high.

          Sit with that like a terrible Zen koan: Medicines are both too cheap and too expensive.

          advertisement

          How is that possible? A lot of it goes back to the 1984 Hatch-Waxman Act, which set up the ecosystem that determines the process by which drugs go from being expensive brands to cheap generics in the U.S.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time

          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

          6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

          read more
          FDA panel to weigh safety of artificial wombs for preterm births
          FDA panel to weigh safety of artificial wombs for preterm births

          AdobeTheartificialwomb,adeviceaimingtosaveinfantsbornwaytoosoon,isinchingclosertobeingtestedinhumans

          read more
          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more

          How medical schools plan to diversify without affirmative action

          Fromlefttoright,toprow:STAT'sUshaLeeMcFarling;Vanderbilt'sConsueloWilkins;CarolinaReyesofUCDavisHeal